Coronado readies IND for Crohn's treatment; Aastrom reaches agreement on SPA for critical limb ischemia study;

@FierceBiotech: Nonprofit poised to reap rewards from Vertex's pioneering CF drug. Article | Follow @FierceBiotech

@JohnCFierce: Under pressure to speed things up, FDA Commissioner Margaret Hamburg is looking to loosen conflict rules for adcomm members. Report | Follow @JohnCFierce

@RyanMFierce: Icon's buyout of clinical tech firm Firecrest motivated by improving trials time lines, efficiency. Story | Follow @RyanMFierce

> Fresh from raising $25.8 million, New York-based Coronado Biosciences says it plans to file an IND with the FDA on a new treatment for Crohn's disease. Report

> Aastrom Biosciences has reached an agreement with the FDA on a Special Protocol Assessment for a Phase III trial of ixmyelocel-T in patients with critical limb ischemia who have no other treatment options. Release

> Australia's CSL Limited has forged a commercial license agreement with Selexis for the preclinical development of an antibody scheduled to enter Phase I next year. CSL release

> In a newly announced strategic partnership, Debiopharm says it will trust INC Research with the management of a clinical study linked to an important project in its pipeline. Both parties have also agreed on a "framework partnership" for future clinical studies. Release

Pharma News

@FiercePharma: Will pharma fight the Express-Medco deal? Piece | Follow @FiercePharma

> Eyes on 2012, GSK pledges more cost cuts. Article

> Novo faces sales-rep action on OT pay. Report

Manufacturing News

> Fictional "Spenditol" gives appearance of feelings of relief, unpleasant side effects. Piece

> Rx-360 concludes pilot; begins sharing of supplier audits. News

> For J&J/McNeil no exec blame for recalls, panel says. Report

> Novartis productivity boss seeks procurement's full potential. Article

> Teva supply chain gets a boost from social media. Story

> Hong Kong tips off Vietnam about contaminated GSK drug. More

Biotech Research News

> Researchers detract last year's discovery of longevity genes. Article

> Enzyme insights could lead to better sunburn treatments. Story

> Genetic map of American Americans gives clues to diseases in all populations. Report

> UK scientists urge regulations of animal/human gene experiments. Item

And Finally... Using new technology, scientists say they have found the brain's on/off switch for aggression. Story

Suggested Articles

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells.